Electrophysiological studies of the GABAA receptor ligand, 4-PIOL, on cultured hippocampal neurones.
U Kristiansen, J D Lambert, E Falch, P Krogsgaard-Larsen
Index: Br. J. Pharmacol. 104(1) , 85-90, (1991)
Full Text: HTML
Abstract
1. Whole-cell, patch-clamp recordings from cultured hippocampal neurones have been used to characterize the action of the GABAA ligand, 5-(4-piperidyl)isoxazol-3-ol (4-PIOL). The action of 4-PIOL was compared with that of the established GABAA agonist, isoguvacine. 2. With a symmetrical Cl- gradient across the membrane and a holding potential of -60mV, both isoguvacine and 4-PIOL evoked an inward current. The reversal potentials of the responses to both agents were identical (+8.8 mV, n = 4) and the current/voltage relationships showed outward-going rectification. 3. The response to 300 microM 4-PIOL was completely blocked by the GABAA antagonist, bicuculline methobromide (BMB, 10 microM). The pA2 of BMB was greater than 6.46. With 2 mM 4-PIOL about 15% of the response remained in the presence of 100 microM BMB. This may represent a non-specific component of the response to large concentrations of 4-PIOL. 4. 4-PIOL was about 200 times less potent as an agonist than isoguvacine. because of the rapid fade (desensitization) of isoguvacine-induced currents, the maximum response to this agonist was not determined. However, the response to 2 mM 4-PIOL was only a small fraction of that evoked by submaximal concentrations of isoguvacine. 5. Setting the response to 1 mM 4-PIOL as maximum, the EC50 for 4-PIOL was 91 microM (95% confidence limits:73-114 microM). 6. 4-PIOL antagonized the response to isoguvacine with a parallel shift to the right of the dose-response curve. The antagonist action of 4-PIOL was about 30 times weaker than that of BMB. When allowance was made for the intrinsic agonist action of 4-PIOL, the Ki was 116p microM (95% confidence limits: 102-130 microM). This was not significantly different from EC5, (P = 0.86; non-parametric Mann-Whitney test).7. It is concluded that 4-PIOL is a partial agonist at the GABAA receptor on cultured hippocampal neurones.
Related Compounds
Related Articles:
2010-12-01
[J. Neurochem. 115(5) , 1112-22, (2010)]
1982-11-01
[Physiol. Behav. 29(5) , 901-4, (1982)]
2003-06-06
[Brain Res. 974(1-2) , 153-66, (2003)]
2011-06-01
[Neuropharmacology 60(7-8) , 1142-53, (2011)]
2000-12-15
[J. Neurosci. 20(24) , 9195-206, (2000)]